NIH R21 Exploratory Research Grant — Parent PA
Supports exploratory developmental research through recurring NIH parent mechanisms in the United States.
The NIH R21 Exploratory/Developmental Research Project Grant supports high-risk, novel research ideas that lack the preliminary data base typically required for an R01. Two parent announcements cover open R21 submissions: PA-25-304 (Clinical Trial Not Allowed) and PA-25-306 (Clinical Trial Required), both released December 18, 2024, and active through January 8, 2028. New application deadlines are February 16, June 16, and October 16 each year; renewals and resubmissions are due March 16, July 16, and November 16. The R21 is intended as a stepping-stone mechanism: reviewers expect less preliminary data than an R01, and the exploratory framing rewards scientific novelty and creative hypothesis formation.
The R21 is capped at two years of support, though total direct cost limits are set by each individual NIH Institute or Center rather than in the parent announcement itself. Eligible applicants include domestic universities, research hospitals, nonprofits, and for-profit organizations with research capacity; individual applicants must hold an institutional affiliation. The mechanism covers any biomedical, behavioral, or clinical research area relevant to a participating NIH IC, making topic alignment with the receiving IC's current portfolio a critical application strategy.
Applications submitted under the parent PA compete across all ICs in a general pool; investigators targeting an IC-specific set-aside should look for R21 applications requested under a Program Announcement with Special Receipt Review Considerations (PAS) or RFA. The review process mirrors the R01: assignment to a study section, numerical scoring, Advisory Council review, and IC-level funding decision. Because the R21 is explicitly designed for exploratory work, applicants should emphasize the innovation and potential impact of their hypothesis rather than established methodology.
Exploratory and developmental biomedical research with high-risk, novel hypotheses across any NIH Institute or Center area, on a three-cycle annual submission schedule.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline